|
Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia |
Dec 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
|
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
Dec 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
|
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
Dec 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
Nov 2020 |
Annals of Oncology: Official Journal of the European Society for Medical Oncology |
Myelodysplastic Syndromes (MDS) |
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease |
Nov 2020 |
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Nov 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
Nov 2020 |
Cells |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
